Sprim

Napo Pharmaceuticals, Inc. is a biotechnology company focused on the development and commercialization of proprietary pharmaceuticals for international markets. Founded in 2001 and headquartered in San Francisco, California, with a subsidiary in Mumbai, India, the company specializes in treatments for gastrointestinal conditions. Napo's main product, Crofelemer, is designed to provide symptomatic relief from noninfectious diarrhea in adult patients living with HIV/AIDS, particularly those undergoing antiretroviral therapy. In addition to Crofelemer, Napo Pharmaceuticals offers a range of products targeting various gastrointestinal indications, including NP-500 for insulin-resistant diseases, CRO-IBS for diarrhea-predominant irritable bowel syndrome, CRO-HIV for AIDS-related diarrhea, CRO-ID for acute infectious diarrhea, and CRO-PED for pediatric diarrhea. The company's mission is to meet the needs of patients in high-margin Western markets while addressing critical health issues associated with gastrointestinal disorders.

RegASK is a global RegTech company that uses artificial intelligence to monitor regulatory changes and ESG issues in real time. The platform provides instant alerts and a full range of services, including real-time regulatory monitoring, risk prediction, compliance support, path-to-market, path-to-claim, product registration, and regulatory strategy for products in the food, dietary supplement, cosmetic, personal care, and medical device industries. The company helps organizations reduce the time and cost of regulatory research and stay ahead of evolving requirements across global markets. RegASK was founded in 2017 by Caroline Shleifer and is headquartered in Singapore.

Mi-Helper develops innovative, non-drug remedies for migraine relief. Their flagship product is a semi-portable device that delivers a fine saline mist into the nostrils, providing on-demand relief from migraine-related pain and associated symptoms.

AUM Biosciences, established in 2018 and headquartered in Singapore, is an oncology-focused biotechnology company. It specializes in the early-stage development of innovative, affordable medicines for the treatment of prevalent cancers, with a focus on those common in Asia. The company's platform leverages AI-augmented technology to discover and develop targeted cancer therapies based on genetic targets, aiming to accelerate drug development and improve patient access to effective treatments. AUM Biosciences serves research institutes, clinicians, and pharmaceutical companies, with a portfolio spanning breast, gastric, hepatocellular, head and neck, and prostate cancers.

ObvioHealth is a global digital health company that provides a real-world digital clinical trials platform. Its mobile study application supports site-less and virtual trials, enabling participants to use smartphones for remote monitoring and continuous data collection between visits. The platform engages participants daily through text messaging and chat features, supporting open communication and higher engagement. It integrates with health devices such as Apple Watch, Fitbits, Bluetooth scales, and blood pressure monitors to collect real-world data, and it can link to lab scheduling and participant compensation systems. When in-person visits are required, the app supports scheduling and remote communication via chat or video. The solution aims to reduce trial inefficiencies, improve data quality, accelerate recruitment, and shorten timelines, while delivering a smoother experience for participants and better data for sponsors.

Magnosco specializes in early-stage skin cancer detection, particularly malignant melanoma. The company has developed a non-invasive diagnostic method known as dermatofluoroscopy, which utilizes infrared laser technology combined with artificial intelligence. This innovative approach enables precise and early detection of malignant melanomas, enhancing the accuracy of dermatological diagnostics. In addition to melanoma, Magnosco's technology also offers potential support for diagnosing other skin tumors and diseases, aiming to improve patient outcomes through advanced medical solutions.

ObvioHealth is a global digital health company that provides a real-world digital clinical trials platform. Its mobile study application supports site-less and virtual trials, enabling participants to use smartphones for remote monitoring and continuous data collection between visits. The platform engages participants daily through text messaging and chat features, supporting open communication and higher engagement. It integrates with health devices such as Apple Watch, Fitbits, Bluetooth scales, and blood pressure monitors to collect real-world data, and it can link to lab scheduling and participant compensation systems. When in-person visits are required, the app supports scheduling and remote communication via chat or video. The solution aims to reduce trial inefficiencies, improve data quality, accelerate recruitment, and shorten timelines, while delivering a smoother experience for participants and better data for sponsors.

ObvioHealth is a global digital health company that provides a real-world digital clinical trials platform. Its mobile study application supports site-less and virtual trials, enabling participants to use smartphones for remote monitoring and continuous data collection between visits. The platform engages participants daily through text messaging and chat features, supporting open communication and higher engagement. It integrates with health devices such as Apple Watch, Fitbits, Bluetooth scales, and blood pressure monitors to collect real-world data, and it can link to lab scheduling and participant compensation systems. When in-person visits are required, the app supports scheduling and remote communication via chat or video. The solution aims to reduce trial inefficiencies, improve data quality, accelerate recruitment, and shorten timelines, while delivering a smoother experience for participants and better data for sponsors.